Trial Profile
A Randomized, Double-blind, Parallel Group Study to Compare the Pharmacodynamics/Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Moderate Persistent Asthma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs QAV 680 (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 14 Apr 2012 New source identified and integrated (EudraCT2009-017267-41: European Clinical Trials Database).
- 16 Sep 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 16 Sep 2010 Planned end date changed from 1 Dec 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.